Company news

Enzolytics Inc. (OTC:ENZC) news

Enzolytics Inc. news releases on 6ix. Latest, Dec 1, 2022: Enzolytics Recognizes World AIDS Day and Highlights the Company's Focus on Producing Effective…

Enzolytics Inc. (OTC:ENZC) news

Press releases — page 2

Enzolytics Recognizes World AIDS Day and Highlights the Company's Focus on Producing Effective Therapies for Treating HIV

Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune(TM)

Enzolytics, Inc. Announces New Advisory Board Member

Enzolytics Reports Successful Completion of an MTD Tolerability Study of Its ITV-1 anti-HIV Therapeutic Leading to the Start of a 28-day GLP Toxicology Study

Enzolytics Inc. Announces Collaboration with Abveris to Discover Monoclonal Antibodies

Enzolytics Inc. Announces Litigation Success, Accounting Progress and Removal of "Yield" Sign on OTC Markets Stock Quotes

Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company's Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.

Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus

CORRECTION: Enzolytics, Inc. Reports Progress and Future Plans

Enzolytics, Inc. Reports Progress and Future Plans

Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS-CoV-2 and HIV Viruses

Enzolytics, Inc. Highlights the Introduction of IPF Immune(TM) as CRN Data Shows Record-Breaking Number of Americans Use Dietary Supplements

Enzolytics, Inc.'s Wholly Owned Subsidiary Virogentics, Inc. Reports Progress on the Delivery of its ITV-1 Anti-HIV Therapeutic for Use by Patients in African Regions

Enzolytics IPF Immune(TM), an Immune Modulator, Is Introduced into the U.S. Market This Month

Enzolytics Announces Its New Technology For Entry Into The In-Vitro Diagnostics Market

Enzolytics, Inc. Announces Production and Sale in North America of “Enzolytics IPF Immune(TM)”, A New Dietary Supplement That Enhances the Immune System

Enzolytics Reports Its Engagement of Scendea USA, Inc., a Leading International Product Development and Regulatory Consulting Group, To Guide the Progress Toward Clinical Trials and Market Approval for Its Itv-1 Anti-HIV Therapeutic

Enzolytics Announces Progress As It Recognizes World AIDS Day

Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune", a Tested Immune Modulator based on U.S. Patent No. 8,309,072

Enzolytics, Inc. Announces Program for Creation of Multiple Monoclonal Antibodies for Veterinary Application Utilizing Hybridoma and Phage Display Technology

Enzolytics Reports Its Progress Toward Completion Of Clinical Trials for Its ITV-1 ANTI-HIV Therapeutic and Securing Use Authorization Under the European Medicines Agency

Enzolytics Announces the Appointment of Steve Sharabura as President of its Wholly Owned Subsidiary RobustoMed, Inc (A/K/A ENZO SUB)

Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics

Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc. for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies

Enzolytics Announces Its Progress Toward Completion of Clinical Trials for Its Anti-HIV ITV-1 Therapeutic and Plans for Its Distribution Throughout Europe

Enzolytics Announces A Comprehensive Therapeutic Protocol For Production Of Monoclonal Antibodies To Address Ongoing And Future Pandemics

Enzolytics Announces the Discovery of Conserved, Immutable Target Sites on HTLV-1 and Plans To Commence Production of Monoclonal Antibodies Targeting These Sites

Enzolytics Inc. and Intel Corporation Co-Author White Paper on Use of Artificial Intelligence for Social Good

Enzolytics, Inc. Announces the Grant of a Distributorship License for the Right to Distribute its Anti-Hiv-1 Therapeeutic Itv-1 and a Stock Agreement Valued in Total At $7 Million US Dollars

Enzolytics, Inc. Announces the Engaement of Ten Associates LLC As The Company's Strategic Communication Firm

Enzolytics Reports Progress On Its Multiple Therapeutics Platforms and Initiatives

Enzolytics to Present At the Emerging Growth Conference on April 14, 2021

CEO Presenting on the Emerging Growth Conference on April 14; Register now

Coronavirus Targeted Epitopes Claimed in Enzolytics' Pending Patent Applications are Verified as Fully Conserved in the UK, Brazil and South African Variants of the Coronavirus (SARS-COV-2)

Enzolytics Announces the Filing of Updated NIH Grant Applications Incorporating Newly Identified Conserved Epitopes on Both the HIV-1 and SARS-CoV-2 Viruses; Other Corporate Updates

Enzolytics Finalizes Documentation with International Medical Partners, Ltd for Clinical Trials and Initial Production of ITV-1 Company Also Provides Update on Year End Reporting

Enzolytics Announces the Discovery and Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus

Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus)

Enzolytics Updates Permitting Progress in Europe on Its Planned Clinical Trials of Its Patented ITV-1 Anti-HIV and Other Developments

Enzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic Diseases

Enzolytics Announces The Discovery Of Seven Newly Identified Conserved Target Sites On The HIV Virus

Enzolytics, Inc. Receives Official Filing Receipt for Multiple Sclerosis Patent Application

Enzolytics, Inc. Engages PCAOB Auditor for December 31, 2020 Year End Audit

Enzolytics, Inc. 2020 Year End Update

Enzolytics, Inc. Engages BTS Research to Conduct Toxicity Study

Enzolytics, Inc. Files Provisional Patent for Treatment of Multiple Sclerosis

Enzolytics, Inc. Completes Merger with BioClonetics Immunotherapeutics, Inc.

Enzolytics Inc. Shares Current BioClonetics Immunotherapeutics, Inc. Update

Enzolytics, Inc. Appoints Ronald Moss, M.D. to Its Medical Advisory Board

Enzolytics, Inc. Announces Appointment of Charles Cotropia as CEO of ENZC and Harry Zhabilov as Its CSO